NCT03647163 - Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 9, 2019

Primary Completion Date

July 31, 2025

Study Completion Date

September 30, 2025

Conditions

Solid TumorNon Small Cell Lung CancerNeuroendocrine CarcinomaRenal Cell Carcinoma (RCC)

Interventions

BIOLOGICAL

VSV-IFNβ-NIS

Intravenous oncolytic Vesicular stomatitis virus (VSV) expressing Interferon-beta (IFNβ) and the sodium iodide symporter (NIS)

BIOLOGICAL

Pembrolizumab

BIOLOGICAL

ipilimumab + nivolumab

Intravenous ipilimumab 1mg/kg in combination with nivolumab 360mg, or Intravenous ipilimumab 1mg/kg in combination with nivolumab 3mg/ kg for 4 cycles, followed by fixed dose nivolumab 480mg

Trial Locations (2)

44195

Cleveland Clinic Taussig Cancer Institute, Cleveland

55905

Mayo Clinic, Rochester